FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898098241> ?p ?o ?g. }

• W2898098241 endingPage "2009" @default.
• W2898098241 startingPage "2001" @default.
• W2898098241 abstract "Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients Lei Yan,1,* Chuanwu Zhu,2,* Jing Li,3,* Liwen Chen,1 Yezhou Ding,1 Zhujun Cao,1 Kehui Liu,1,4 Lanyi Lin,1 Weiliang Tang,1 Qing Xie,1 Yumin Xu,1 Shisan Bao,5 Hui Wang1 1Department of Infectious Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2Department of Infectious Diseases, The Fifth People’s Hospital of Suzhou, Jiangsu 215007, China; 3Department of Infectious Diseases, Huai-An Fourth People’s Hospital, Jiangsu 223002, China; 4Department of Infectious Diseases, Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China; 5Discipline of Pathology, School of Medical Sciences and Bosch Institute, Charles Perkin Centre, University of Sydney, Sydney, NSW, Australia *These authors contributed equally to this work Background and aims: Chronic hepatitis B (CHB) patients rarely achieve hepatitis B surface antigen (HBsAg) loss with nucleoside/nucleotide analog therapy. Methods: In this retrospective study, it was evaluated that the rate of HBsAg loss in the HBe antigen negative (HBeAg−) patients (n=101) treated with entecavir (ETV) for ≥24 weeks followed by switching to (n=22) or adding on (n=26) pegylated interferon (PEG-IFN), and continuing ETV (n=53). Results: HBsAg clearance rate at week 48 was 9% (2/22), 15% (4/26), and 0% (0/53) (P<0.05), in switch-to or add-on, or ETV monotherapy CHB patients, respectively. HBsAg reduction at week 48 was 1.182, 0.6614, or 0.056 log IU/mL, in switch-to, add-on, and ETV patients, respectively (P<0.001). The response rate (HBsAg reduction >1 log IU/mL at week 48) in the switch-to, add-on, and ETV monotherapy CHB patients was 60%, 40%, and 2%, respectively (P<0.001). In the switch-to and add-on patients, HBsAg reduction and clearance were associated with HBsAg titers at week 0 and HBsAg reduction at week 24. Furthermore, HBsAg reduction at week 24 was associated with the response rate at week 48 in the switch-to and add-on patients, showing that the area under the receiver operating characteristic curve was 0.904. Positive predictive value and negative predictive value for response rate was 70% and 100% with cut-off value 0.2 log IU/mL, respectively. Conclusion: In summary, we demonstrated that PEG-IFN enhanced HBsAg loss in HBeAg− CHB patients. High HBsAg clearance was achieved in the patients with HBsAg titers at baseline <1,000 IU/mL and HBsAg reduction >0.2 log IU/mL. Keywords: chronic hepatitis B, HBsAg, PEG-IFN, entecavir, switch-to, add-on" @default.
• W2898098241 created "2018-11-02" @default.
• W2898098241 creator A5002747282 @default.
• W2898098241 creator A5008310752 @default.
• W2898098241 creator A5026919394 @default.
• W2898098241 creator A5034309002 @default.
• W2898098241 creator A5042069878 @default.
• W2898098241 creator A5045138416 @default.
• W2898098241 creator A5063064112 @default.
• W2898098241 creator A5063942792 @default.
• W2898098241 creator A5075854846 @default.
• W2898098241 creator A5084445748 @default.
• W2898098241 creator A5086690723 @default.
• W2898098241 creator A5090366405 @default.
• W2898098241 creator A5090474210 @default.
• W2898098241 date "2018-10-01" @default.
• W2898098241 modified "2023-09-27" @default.
• W2898098241 title "Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients" @default.
• W2898098241 cites W1967001578 @default.
• W2898098241 cites W1984234971 @default.
• W2898098241 cites W2005657634 @default.
• W2898098241 cites W2017949539 @default.
• W2898098241 cites W2020276240 @default.
• W2898098241 cites W2028770751 @default.
• W2898098241 cites W2032812836 @default.
• W2898098241 cites W2042565956 @default.
• W2898098241 cites W2076974448 @default.
• W2898098241 cites W2088437131 @default.
• W2898098241 cites W2089153567 @default.
• W2898098241 cites W2094798000 @default.
• W2898098241 cites W216121951 @default.
• W2898098241 cites W2169631718 @default.
• W2898098241 cites W2172066280 @default.
• W2898098241 cites W2173007581 @default.
• W2898098241 cites W2181609972 @default.
• W2898098241 cites W2579544732 @default.
• W2898098241 cites W2587782086 @default.
• W2898098241 cites W2605785536 @default.
• W2898098241 cites W2742618178 @default.
• W2898098241 cites W2768065696 @default.
• W2898098241 doi "https://doi.org/10.2147/idr.s175707" @default.
• W2898098241 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6211310" @default.
• W2898098241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30464542" @default.
• W2898098241 hasPublicationYear "2018" @default.
• W2898098241 type Work @default.
• W2898098241 sameAs 2898098241 @default.
• W2898098241 citedByCount "13" @default.
• W2898098241 countsByYear W28980982412019 @default.
• W2898098241 countsByYear W28980982412020 @default.
• W2898098241 countsByYear W28980982412021 @default.
• W2898098241 countsByYear W28980982412022 @default.
• W2898098241 countsByYear W28980982412023 @default.
• W2898098241 crossrefType "journal-article" @default.
• W2898098241 hasAuthorship W2898098241A5002747282 @default.
• W2898098241 hasAuthorship W2898098241A5008310752 @default.
• W2898098241 hasAuthorship W2898098241A5026919394 @default.
• W2898098241 hasAuthorship W2898098241A5034309002 @default.
• W2898098241 hasAuthorship W2898098241A5042069878 @default.
• W2898098241 hasAuthorship W2898098241A5045138416 @default.
• W2898098241 hasAuthorship W2898098241A5063064112 @default.
• W2898098241 hasAuthorship W2898098241A5063942792 @default.
• W2898098241 hasAuthorship W2898098241A5075854846 @default.
• W2898098241 hasAuthorship W2898098241A5084445748 @default.
• W2898098241 hasAuthorship W2898098241A5086690723 @default.
• W2898098241 hasAuthorship W2898098241A5090366405 @default.
• W2898098241 hasAuthorship W2898098241A5090474210 @default.
• W2898098241 hasBestOaLocation W28980982411 @default.
• W2898098241 hasConcept C126322002 @default.
• W2898098241 hasConcept C147483822 @default.
• W2898098241 hasConcept C159047783 @default.
• W2898098241 hasConcept C203014093 @default.
• W2898098241 hasConcept C2522874641 @default.
• W2898098241 hasConcept C2775940106 @default.
• W2898098241 hasConcept C2776175608 @default.
• W2898098241 hasConcept C2776461080 @default.
• W2898098241 hasConcept C2777382497 @default.
• W2898098241 hasConcept C2777410769 @default.
• W2898098241 hasConcept C2777869810 @default.
• W2898098241 hasConcept C2780040827 @default.
• W2898098241 hasConcept C2780593183 @default.
• W2898098241 hasConcept C3020491458 @default.
• W2898098241 hasConcept C556039675 @default.
• W2898098241 hasConcept C71924100 @default.
• W2898098241 hasConcept C90924648 @default.
• W2898098241 hasConceptScore W2898098241C126322002 @default.
• W2898098241 hasConceptScore W2898098241C147483822 @default.
• W2898098241 hasConceptScore W2898098241C159047783 @default.
• W2898098241 hasConceptScore W2898098241C203014093 @default.
• W2898098241 hasConceptScore W2898098241C2522874641 @default.
• W2898098241 hasConceptScore W2898098241C2775940106 @default.
• W2898098241 hasConceptScore W2898098241C2776175608 @default.
• W2898098241 hasConceptScore W2898098241C2776461080 @default.
• W2898098241 hasConceptScore W2898098241C2777382497 @default.
• W2898098241 hasConceptScore W2898098241C2777410769 @default.
• W2898098241 hasConceptScore W2898098241C2777869810 @default.
• W2898098241 hasConceptScore W2898098241C2780040827 @default.
• W2898098241 hasConceptScore W2898098241C2780593183 @default.
• W2898098241 hasConceptScore W2898098241C3020491458 @default.

• next